PMH1 Evaluation of Factors Affecting Treatment Response and Risk Factors for Patients Diagnosed with Non-Psychotic Major Depressive Disorder: A Literature Review  by Greene, N. & Greene, M.
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 6 6 5 – A 7 2 8  A693
Gastrointestinal DisorDers – Patient-reported outcomes & Patient  
Preference studies
PGi8
Quality of life in Patients with GastroesoPhaGeal reflux Disease in 
slovakia
Bielik J.1, Marusakova E.2, Matisakova I.1, Gerlichova K.3
1Trencin University of Alexander Dubcek, Trencin, Slovak Republic, 2GlaxoSmithKline Slovakia, 
Bratislava, Slovak Republic, 3Trencin University, Trencin, Slovak Republic
Objectives: The estimated prevalence of complicated gastroesophageal reflux dis-
ease (GERD) is approximately 2% in the European population and showing 10-fold 
increase over the past 20 years. The objective of this paper was to find out the level 
of QoL in patients with GERD in Slovakia. MethOds: The primary method used for 
the analysis of QoL was the presence of transient disability period and combined 
questionnaire consisting of 4 parts: A. Demography and socioeconomics (13 items), 
B. Generic questionnaire (SF-36), C. Visual scale (4 items), D. Complementary (infor-
mation and habits, 13 items). The Likert scale was used in closed questions. The 
sample included 100 patients treated in the gastroenterological outpatient clinic 
(34 men and 66 women). Of these, 72 patients were in productive age. The patients 
were chosen according to the order in which they visited the clinic. Results: One 
month and two months of sick days were recorded in 8.3% and 7% of patients, 
respectively; 84,7% of patients did not report any sick days. The loss of money of 
up to 400 € and between 401 and 800 € was recorded in 11.1% and 4.2 % of patients, 
respectively; 84.3 % of did not report any loss of money. Present level of QoL was 
identified as 5.12 on the scale of 10, while in the time of the GERD diagnosis it was 
3.86. QoL was 8.25 in the time without GERD and 8.17 in optimal state of health, 
respectively. Future expectations were perceived as positive in 56% of patients and 
negative in 44% of patients. cOnclusiOns: A total of 95% of patients were well 
and very well informed about its characteristics. Paradoxically, only 48% of them 
used their medications regularly, although regular and occasional administration 
of medications was shown to have positive impact on health status in 56% and 44% 
of patients, respectively.
Gastrointestinal DisorDers – health Care use & Policy studies
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a low antiviral treatment rate in ChroniC hePtitis C Patients in 
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Objectives: Hepatitis C virus (HCV) infection is the most common cause of liver 
cirrhosis and liver cancer worldwide. In addition to low disease awareness both in 
public and affected patients, a low disease treatment rate remains to be an impor-
tant issue regarding disease control in primary care. The nationwide prevalence 
of anti-HCV seropositivity in Taiwan is 4.4%. However, there are scattered hyper-
endemic areas in Southern Taiwan with an extremely high prevalence rate reaches 
57.9% high. Therefore, several public health strategies with periodic assessment 
aiming to promote liver health have been performed for two decades. MethOds: 
We aimed to elucidate the reasons of lower treatment rate in our country. In this 
hospital-based, physician-oriented study, a proportional sampling based on previous 
documented HCV prevalence of geographic locations in Taiwan was conducted. An 
anonymous questionnaire regarding treatment status in anti-HCV-positive patients 
was collected from these selected physicians. Patient’s information including sex, 
age, anti-HCV therapy, and the reason for not receiving antiviral therapy was 
inquired by their primary care physicians. Results: Seventy-six physicians were 
recruited into this survey (Medical center n= 46; regional hospital n= 23; primary 
clinic n= 7). A total of 2,722 anti-HCV-positive subjects in Taiwan were enrolled into 
this analysis. Among them, 54.5% (1,479/2,722) had ever received anti-HCV treat-
ment before. The treatment rate of medical centers was 63.1%, which was higher 
than 52.7% of regional hospitals, and 33.8% of primary clinics, respectively (p< 0.0001 
for pair-wise chi square test; p< 0.0001 for trend test). Males had a significantly 
higher motivation for receiving antiviral therapy than females (58.6% vs. 50.5%, 
p< 0.0001). The main reason for not receiving anti-HCV therapy was fear of side 
effects (38%), followed by ineligibility for insurance reimbursement (18%), and lack 
of awareness (11%). cOnclusiOns: In Taiwan, half of the HCV-infected patients 
have not received antiviral therapy. The low treatment rate may contribute to HCV 
hyperendemic status.
mental health – Clinical outcomes studies
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evaluation of faCtors affeCtinG treatment resPonse anD risk 
faCtors for Patients DiaGnoseD with non-PsyChotiC major 
DePressive DisorDer: a literature review
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Objectives: To conduct a systematic review of literature on factors that are 
affecting patient treatment response and risk factors for patients diagnosed 
with Non-Psychotic Major Depressive Disorder (MDD). MethOds: A literature 
search was performed using relevant search terms to identify articles published 
from 2000 to 2010 on the factors affecting treatment response and risk factors 
for MDD. Studies were identified through electronic Embase, Cochrane, Medline, 
and PubMed databases. Additional parameters were placed on the final search 
strategy to limit the retrieval to articles written in English, involving human 
subjects. Results: The initial search revealed 874 articles for factors affecting 
treatment response and 590 articles for risk factors affecting MDD from PubMed/
Medline/Embase/Cochrane databases. After removing duplicates and non-rele-
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Objectives: Direct acting antiviral therapies (DAA) in addition to PEG 2a + RBV 
(PR) are a new therapeutic option with higher rates of sustained virological 
response (SVR) than dual therapy (PR) alone in chronic hepatitis C. Currently, 
two alternatives of DAA, telaprevir (TVR) and boceprevir (BOC), are available in 
Chile. The aim of this study was to evaluate the cost-effectiveness of adding TVR 
to PR in treatment naive and previously treated patients with HCV in Chile com-
pared to PR alone and with the addition of BOC. MethOds: A lifetime Markov 
model was developed including HCV, cirrhosis, liver transplant and death as 
health states. QALYs as an outcome measure, a health care system perspective 
and a 6% discount rate for health benefits and costs have been used. Costs are 
expressed in local currency. A review of the literature to obtain epidemiologic 
and resources utilization data was performed and when data were not avail-
able or validation was needed a Delphi panel with local experts was carried out. 
Deterministic and probabilistic sensitivity analysis was performed. Results: 
In comparison with PR, TVR avoided 174 cirrhosis cases and 16 deaths per 1,000 
patients and shown an ICER of $14,730,736/QALY and $8,300,511/QALY for the 
naïve and for the previously treated patients respectively. TVR dominated BOC 
in naïve patients and in most of the previously treated ones (was less costly 
and more efficacious), except in the partial responders subgroup. Against the 
WHO criteria TVP versus PR presented 80% of probability of being cost effective 
for naïve and 96% of probability of being cost effective for previously treated 
patients. cOnclusiOns: TVR dominated BOC and was cost-effective against 
WHO 3x GDP criteria in comparison to double therapy from the national health 
care system perspective in Chile.
PGi6
eConomiC evaluation of DireCt aCtinG antiviral (Daa) treatments 
for hePatitis C virus (hCv) infeCtion in Previously treateD Patients 
from the Peruvian health Care system PersPeCtive
Ariza J.G.1, Hinojosa R.2
1Janssen Cilag, Bogotá, Colombia, 2Janssen Cilag Peru, Lima, Peru
Objectives: DAA treatments in addition to Ribavirin (RBV) and peginterferon 
(Peg-INF) (PR), provides the greatest opportunity to fully achieve sustained viro-
logical response (SVR) in HCV infected patients. Currently, two alternatives of 
DAA, telaprevir (TVR) and boceprevir (BOC), are available in Peru. The objective 
of this study is to assess: which is the most efficient DAA treatment to compli-
ment the PR in previously treated patients. MethOds: A Markov model was 
used from the payer perspective to estimate costs and benefits throughout the 
whole life. Transition probabilities, utilities and resources usage were obtained 
from literature and through a mixed treatment comparison. Only direct costs 
were considered as medications, laboratory tests, complications costs and 
adverse events by using tariffs and tender prices from EsSalud. Outcomes were 
measured as SVR, quality adjusted life years (QALY) and events of cirrhosis per 
1,000 treated patients. Two alternatives were assessed: 1) 12 weeks of TVR plus 
PR and 2) 24-44 weeks of BOC plus PR. Discount rate 3% and exchange rate (1 
USD = 2,6 S/). Results: 1) Total costs (USD): TVR plus PR ($56,058), BOC plus PR 
($64,536). 2) Medication costs (USD): TVR plus PR ($47,297), BOC plus PR ($54,649). 
3) SVR: TVR plus PR (76%), BOC plus PR (60%). 4) QALY: TVR plus PR (6,02), BOC 
plus PR (5,87). 5) Cirrhosis per 1,000 treated patients: TVR plus PR (311), BOC plus 
PR (363). Incremental Cost Effectiveness Ratio (ICER) was negative, showing that 
12 weeks of TVR plus PR is a dominant therapy. cOnclusiOns: When a DAA is 
considered, in addition to PR, for previously treated patients, TVR is the preferred 
choice because of its potential cost-savings versus BOC and incremental health 
benefits versus BOC.
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Objectives: Direct acting antiviral therapies (DAA) in addition to PEG 2a + 
RBV (PR) are a new therapeutic option with higher rates of sustained virologi-
cal response (SVR) than dual therapy (PR) alone in chronic hepatitis C (HCV). 
Currently, two alternatives of DAA, telaprevir (TVR) and boceprevir (BOC), 
are available in Colombia. The aim of this study was to evaluate the cost-
effectiveness of adding TVR to PR in treatment naive and previously treated 
patients with HCV in Colombia compared to PR alone and with the addition 
of BOC. MethOds: A lifetime Markov model was developed including HCV, 
cirrhosis, liver transplant and death as health states. QALYs as an outcome 
measure, a health care system perspective and a 3% discount rate for health 
benefits and costs have been used. Costs are expressed in local currency. A 
review of the literature to obtain epidemiologic and resources utilization data 
was performed and when data were not available or validation was needed a 
Delphi panel with local experts was carried out. Deterministic and probabilis-
tic sensitivity analysis was performed. Results: In comparison with PR, TVR 
avoided 172 cirrhosis cases and 24 deaths per 1,000 patients and shown an ICER 
of $21,260,647/QALY and $8,461,107/QALY for the naïve and for the previously 
treated patients respectively. TVR dominated BOC in naïve patients and in most 
of the previously treated ones (was less costly and more efficacious), except 
in the partial responders subgroup. These results were robust in the sensitiv-
ity analysis. cOnclusiOns: TVR dominated BOC and and was cost-effective 
against WHO 3x GDP criteria in comparison to PR from the national health care 
system perspective in Colombia.
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Objectives: To conduct a systematic review of literature in on epidemiology and 
economic studies for patients diagnosed with Non-Psychotic Major Depressive 
Disorder (MDD). MethOds: The initial search strategy was developed in the 
PubMed/Medline database, and was then translated for the Cochrane and Embase 
database searches. Search strings for epidemiology and economics studies for MDD 
were constructed using varied approaches that included the use of MeSH terms, 
as well as keywords that would afford the best retrieval. Search statements were 
then combined to produce a final search set. Additional parameters were placed on 
the final search strategy to limit the retrieval to articles written in English, involv-
ing human subjects and published between 2000 and 2010. Results: Our search 
revealed 289 articles for epidemiology and 200 articles for economic studies on 
MDD from PubMed/Medline/Embase/Cochrane databases. After removing dupli-
cates and non-relevant articles, 17 for epidemiology and 26 for economic studies 
were included in the final analysis. Fifteen studies on epidemiology were focused 
on MDD prevalence, one study was on cumulative incidence. Prevalence estimates 
were higher for lifetime than past year and ranged between 3.1% and 26.6% for life-
time prevalence and between 1.5% and 11.7% for past-year prevalence. Two studies 
examined burden of illness, one study budgetary impact of MDD, 14 studies exam-
ined cost effectiveness of MDD treatments, 3 studies examined cost utility analysis 
and 6 other studies examined retrospective claims analysis. cOnclusiOns: MDD 
prevalence was higher in the lifetime estimates, when compared to the estimates 
reflecting shorter time frames, although there appeared to be greater variability in 
the lifetime estimates. Overall, the cost of treating MDD varied with type of study, 
study time frame, study perspective, the year in which the costs were calculated, 
and the pharmacotherapy prescribed.
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Objectives: To perform a systematic review of literature in peer-reviewed 
journals on clinical biomarkers, correlates and treatment efficacy in clinical 
studies on patients diagnosed with Non-Psychotic Major Depressive Disorder 
(MDD). MethOds: The initial search strategy was developed in the PubMed/Medline 
database and was then translated for the Cochrane and Embase database searches. 
Search strings for biomarkers, correlates and treatment efficacy in patients with 
MDD were constructed using varied approaches that included the use of MeSH 
terms, as well as keywords that would afford the best retrieval. Also included were 
search terms that used an asterisk as a wildcard applied to a word stem. Search 
statements were then combined to produce a final search set. Additional parameters 
were placed on the final search strategy to limit the retrieval to articles written in 
English, involving human subjects and published between 2000 and 2010. Results: 
The initial search revealed 871 articles from PubMed/Medline/Embase/Cochrane 
databases. After removing duplicates and non-relevant articles, the final articles 
that were included in the review were 131. Forty-eight studies examined biomarkers 
and primarily focused on the relationship between biomarkers and MDD treat-
ment response. Only 29 of the 48 studies found a significant association between a 
biomarker and treatment response. Twenty-nine studies examined MDD correlates 
such as comorbidity or demographic variables. A poorer response to treatment was 
found for those patients who experienced comorbid anxiety, irrespective of the 
type of treatment. Fifty-four studies focused on treatment efficacy and are divided 
into 3 groups: SSRIs only, SNRIs only, and a comparison across SSRIs, SNRIs, and 
bupropion. Overall, the SSRIs showed comparable efficacy when compared to each 
other or placebo. cOnclusiOns: Most of the biomarker studies examined associa-
tions between the serotonin transporter and response to various MDD treatments. 
The majority of efficacy studies found that the treatments that are within the class 
had comparable efficacy.
mental health – Cost studies
Pmh6
the imPaCt of antiPsyChotiCs PolyPharmaCy on health Care Costs 
of PeoPle with mental DisorDers in são Paulo City, Brazil
Razzouk D., Sousa A., Oliveira G.G., Cardoso A., Mari J.J.
Universidade Federal de Sao Paulo, SAO PAULO, Brazil
Objectives: Antipsychotics polypharmacy (AP) has been associated with more 
adverse drug effects, higher treatment costs, worse clinical outcomes and sudden 
death. Though, the frequency of such practice may reach 50 % in some clinical set-
tings. The aims of this study were to estimate AP costs and its influence on the direct 
costs of health care package in a sample of people with mental disorders in São Paulo 
city, Brazil. MethOds: We used a bottom-up approach for the estimation of direct 
costs according to public health service provider perspective. Direct costs included 
costs with accomodation (residential service), inpatient, outpatient and emergency 
services and treatment received in the previous month, in 147 subjects with mental 
disorders living in twenty residential services during the year 2011. We evaluated 
quality of life, social behavior problems, psychiatric diagnosis, severity of symptoms, 
sociodemographics characteristics and pattern of health service use. Results: AP 
was found in 38% of the sample and it was not related with gender, age, severity of 
psychiatric symptoms, quality of life and social behavior problems. Antipsychotics 
monotherapy costs were related with the type of antipsychotic: Atypical antipsychot-
vant articles, the final articles that were considered for review were 82 for treat-
ment response and 13 for risk factors. Fifty-one studies examined non-genetic 
factors, serotonin-related genetic factors and variety of genes and polymorphism 
biomarkers to determine their association with MDD treatment response. Thirty-
one studies focused on variables that were found to be associated with some 
aspect of MDD and their impact on treatment response and include: comor-
bidity (n= 12), demographic and socioeconomic (n= 6), and depression-related 
(n= 13) variables. Thirteen studies examined the risk factors for MDD. Of these, 2 
studies focused on the role of biomarkers in MDD risk. And, 11 studies focused 
on variables that were found to be associated with some aspect of MDD and 
their impact on MDD risk, and focused on comorbidity (n= 5), demographic and 
socioeconomic (n= 2), depression-related (n= 3), and environmental variables 
(n= 1). cOnclusiOns: The majority of the biomarker studies examined associa-
tions between the serotonin transporter, genes and polymorphisms in response 
to various MDD treatments. With respect to correlate studies, younger age of MDD 
onset, as well as family history of mood disorders, were both associated with a 
longer duration of MDD illness.
Pmh2
lenGth of stay anD outComes for aDolesCents treateD for 
suBstanCe use DisorDer: an analysis of Dose resPose usinG 
ProPensity sCores
Ciesla J.1, Mazurek K.2
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Objectives: This research uses propensity score methods to identify the relation-
ship between amount of treatment and treatment outcome for adolescents with 
psychoactive substance use disorder (PSUD). The objective is to describe the dose 
response relationship in terms relevant in economic evaluation. Outcomes studies 
in this population show that longer treatment leads to more positive outcomes. 
The standard for residential programs is a minimum of 21 days of treatment and 
ideally up to 90 days. MethOds: The subjects are 377 adolescents who success-
fully completed primary treatment from 2004-2010. All were placed at ASAM level 
III.5 (Clinically-Managed, Medium/High Intensity Residential). The data are from 
treatment records and a 234-item questionnaire. The questionnaire responses were 
matched to variables in treatment records creating a rich source of pre-treatment 
characteristics. This research operationalizes dose with four one-month categories 
(1 dose= 1 month) to capture nonlinearities between service use and outcomes. The 
outcome is three-month post-treatment drug/alcohol abstinence. The categories 
were fairly even and captured 92% of variation in dose. The first stage of statistical 
analysis used multinomial logistic regression to predict dosage with pre-treatment 
variables while adjusting for characteristics influencing both dose and treatment 
outcome. Propensity scores were then created for each dosage category. The dose 
response relationship was assessed using a binomial logistic regression includ-
ing the four dose categories as dummy variables (lowest dose category as refer-
ence). Results: The overall relationship between dose and outcome was significant 
(p= 0.01) as were outcome improvements over the four doses. Improvements were 
significant (p≤ 0.01) decreasing as dose increased—Exp.(B) was1.204 (1.2 times 
more likely to abstain) for one month, 1.532 two months, 1.643 three months, and 
1.794 for four months (% correctly classified= 94.2; – 2LL= 44.712; Cox and Snell 
R2= 0.475.) cOnclusiOns: This research shows a significant dose response rela-
tionship between treatment length and treatment outcome with response dimin-
ishing on the margin.
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Objectives: To compare treatment outcomes in patients with major depressive dis-
order (MDD) treated with either duloxetine or a selective serotonin reuptake inhibi-
tor (SSRI) for up to 6 months in a naturalistic setting in Mexico. MethOds: Data in 
this post hoc analysis were taken from a 6-month prospective, non-interventional, 
observational study that included a total of 1,549 MDD patients without sexual 
dysfunction in twelve countries (N= 591 in Mexico). Depression severity was meas-
ured using the Clinical Global Impression (CGI) and the 16-item Quick Inventory of 
Depressive Symptomatology Self-Report (QIDS-SR16). Pain was measured using the 
pain related items of the Somatic Symptom Inventory (SSI), and quality of life (QoL) 
was measured using the EQ-5D instrument with the UK population tariff and the 
EQ-VAS. Probabilities of initiating duloxetine (vs. SSRIs), expressed as propensity 
scores, were first constructed using logistic regression. Mixed effects modelling 
with repeated measures (MMRM) analysis was then used to compare treatment 
effectiveness and QoL between the duloxetine (N= 168) and SSRI (N= 413) groups, 
controlling for the propensity scores and other patient characteristics. Results: 
The severity of depression was comparable between the two groups at baseline. 
Duloxetine-treated patients, however, had a higher level of pain severity and a 
lower level of QoL (EQ-5D) than SSRI-treated patients at baseline (p≤ 0.001). Both 
descriptive and MMRM regression analyses showed that patients treated with dulox-
etine had better outcomes during follow-up, compared with patients treated with 
SSRIs. At 6 months, duloxetine-treated patients had lower levels of CGI (2.25 vs. 
2.52, p= 0.005), QIDS-SR16 (3.95 vs. 5.35, p< 0.001), and SSI-pain related (8.52 vs. 9.64, 
p< 0.001), and higher levels of EQ-5D (0.92 vs. 0.87, p< 0.001) and EQ-VAS (64.62 vs. 
57.63, p= 0.006) (MMRM results). cOnclusiOns: Duloxetine-treated patients had 
better 6-months outcomes in terms of depression severity, pain and QoL, compared 
with SSRI-treated patients.
